# Yt Blood Group System

#### Number of antigens 2

High prevalence Yt<sup>a</sup>
Polymorphic Yt<sup>b</sup>

#### **Terminology**

ISBT symbol (number) YT (011) Obsolete name Cartwright

History Named after the high prevalence antigen, Yta;

became a system in 1964 after discovery of the

antithetical antigen.

#### **Expression**

Other blood cells Not on lymphocytes, granulocytes or monocytes

Tissues Brain, muscle, nerves

#### Gene

Chromosome 7q22.1 Name *YT (ACHE)* 

Organization 6 exons distributed over 2.2 kbp of gDNA (exons 5

and 6 are alternatively spliced)

Product Acetylcholinesterase (AChE)



#### **Database accession numbers**

GenBank M55040 (mRNA); L42812 (DNA)

Entrez Gene ID 43

#### Molecular bases of Yt phenotypes

The reference allele, *YT\*01* or *YT\*A* (Accession number M55040) encodes Yt<sup>a</sup> (YT1). Nucleotide differences from this reference allele, and the amino acids affected, are given.

| Allele<br>encodes      | Allele<br>name                 | Exon   | Nucleotide         | Amino acid             | Ethnicity (prevalence)   |
|------------------------|--------------------------------|--------|--------------------|------------------------|--|
| Yt(a-b+)<br>or YT:-1,2 | <i>YT*02.01</i> or <i>YT*B</i> | 2      | 1057C>A            | His353Asn              | Israeli Jews,<br>Israeli Arabs,<br>Druse > Blacks<br>> Europeans<br>(Common) |
| Yt(a-b+)<br>or YT:-1,2 | <i>YT*02.02</i> or <i>YT*B</i> | 2<br>5 | 1057C>A<br>1775C>G | His353Asn<br>Pro592Arg | Israeli Arabs,<br>Druse, and Jews  |


### Amino acid sequence<sup>1</sup>

| MRPPQCLLHT | PSLASPLLLL | LLWLLGGGVG | AEGREDAELL | VTVRGGRLRG | 50  |
|------------|------------|------------|------------|------------|-----|
| IRLKTPGGPV | SAFLGIPFAE | PPMGPRRFLP | PEPKQPWSGV | VDATTFQSVC | 100 |
| YQYVDTLYPG | FEGTEMWNPN | RELSEDCLYL | NVWTPYPRPT | SPTPVLVWIY | 150 |
| GGGFYSGASS | LDVYDGRFLV | QAERTVLVSM | NYRVGAFGFL | ALPGSREAPG | 200 |
| NVGLLDQRLA | LQWVQENVAA | FGGDPTSVTL | FGESAGAASV | GMHLLSPPSR | 250 |
| GLFHRAVLQS | GAPNGPWATV | GMGEARRRAT | QLAHLVGCPP | GGTGGNDTEL | 300 |
| VACLKTRPAQ | VLVNHEWHVL | PQESVFRFSF | VPVVDGDFLS | DTPEALINAG | 350 |
| DFHGLQVLVG | VVKDEGSYFL | VYGAPGFSKD | NESLISRAEF | LAGVRVGVPQ | 400 |
| VSDLAAEAVV | LHYTDWLHPE | DPARLREALS | DVVGDHNVVC | PVAQLAGRLA | 450 |
| AQGARVYAYV | FEHRASTLSW | PLWMGVPHGY | EIEFIFGIPL | DPSRNYTAEE | 500 |
| LIFAQRLMRY | WANFARTGDP | NEPRDPKAPQ | WPPYTAGAQQ | YVSLDLRPLE | 550 |
| VRRGLRAQAC | AFWNRFLPKL | LSATASEAPS | TCPGFTHGEA | APRPGLPLPL | 600 |
| LLLHQLLLLF | LSHLRRL    |            |            |            | 617 |

YT encodes a signal peptide of 31 amino acids, which is cleaved from the membrane bound protein. The carboxyl-terminal 29 amino acids are cleaved from the RBC GPI-linked form.

#### **Carrier molecule**

GPI-linked glycoprotein that probably exists as a dimer in the RBC membrane.



 $M_r$  (SDS-PAGE) 160,000 (72,000 as monomer under reducing

conditions)

CHO: N-glycan 3 sites CHO: O-glycan Present

Cysteine residues 8

Copies per RBC 7,000–10,000 (or 3,500–5,000 dimers)

#### **Function**

AChE terminates nerve impulse transmission. AChE is in many tissues in various forms as a result of alternative splicing and post-translational modification. Function in RBC unknown.

#### Disease association

PNH III RBCs are deficient in AChE. Levels are reduced in myelodysplasias associated with chromosome 7 abnormalities and in some cases of SLE.

### Phenotypes (% occurrence)

| Phenotype               | Most populations             | Israelis                 |
|-------------------------|------------------------------|--------------------------|
| Yt(a+b-)                | 91.9                         | 74.4                     |
| Yt(a+b+)                | 7.8                          | 23.7                     |
| Yt(a-b+)                | 0.3                          | 1.9                      |
| Null: Inherited Yt(a–b- | –) phenotype not found       |                          |
| Unusual: One examp      | le of transient Yt(a-b-) RBC | Cs reported <sup>2</sup> |

#### References

- <sup>1</sup> Bartels, C.F., et al., 1993. Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. Am J Hum Genet 52, 928–936.
- <sup>2</sup> Rao, N., et al., 1993. Human erythrocyte acetylcholinesterase bears the Yt<sup>a</sup> blood group antigen and is reduced or absent in the Yt(a-b-) phenotype. Blood 81, 815–819.

### Yta Antigen

### **Terminology**

ISBT symbol (number) YT1 (011001 or 11.1)

Obsolete name Cartwright

History In 1956 when the antibody to this high-prevalence

antigen was found, most letters in the patient's name (Cartwright) had been taken by other antigens. The authors thought "why not T?" but to avoid confusion with T polyagglutination, they then said "why T" or "Yt". The Yt<sup>a</sup> antigen achieved system status in 1964

after discovery of the antithetical antigen.

#### Occurrence

Most populations >99.8% Israeli Jews 98.6% Israeli Arabs 97.6% Israeli Druse 97.4%

### **Antithetical antigen**

 $Yt^b (YT2)$ 

#### **Expression**

Cord RBCs Weak

Altered Weak or absent from PNH III RBCs

#### Molecular basis associated with Yta antigen1

Amino acid His353

Nucleotide C at bp 1057 in exon 2

### Effect of enzymes and chemicals on Yta antigen on intact RBCs

Ficin/Papain Sensitive (variable)

DTT 200 mM/50 mM Sensitive/weakened (thus sensitive to WARM<sup>TM</sup> and

ZZAP)

Acid Resistant

#### In vitro characteristics of alloanti-Yta

Immunoglobulin class IgG (some are IgG4)

Optimal technique IAT Complement binding Some

### Clinical significance of alloanti-Yta

Transfusion reaction No to moderate (rare)/delayed

HDFN No

#### **Comments**

A report of an apparent alloanti-Yt<sup>a</sup> in a Yt(a+) person suggests the possibility of heterogeneity of the Yt<sup>a</sup> antigen<sup>2</sup>.

Experts agree that anti-Yt<sup>a</sup> are often benign and antigen-negative blood may not need to be transfused.

#### References

<sup>1</sup> Bartels, C.F., et al., 1993. Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. Am J Hum Genet 52, 928–936.

## Ytb Antigen

### Terminology

ISBT symbol (number) YT2 (011002 or 11.2)

History Identified in 1964 and named when its antithetical

relationship to Yta was recognized.

#### **Occurrence**

Europeans 8%
Israeli Jews 21.3%
Israeli Arabs 23.5%
Israeli Druse 26%

Not found in Japanese.

### Antithetical antigen

Yta (YT1)

### **Expression**

Cord RBCs Weak

Altered Weak or absent from PNH III RBCs

<sup>&</sup>lt;sup>2</sup> Mazzi, G., et al., 1994. Presence of anti-Yt<sup>a</sup> antibody in a Yt(a+) patient. Vox Sang 66, 130–132.

### Molecular basis associated with Ytb antigen1

Amino acid Asn353

Nucleotide A at bp 1057 in exon 2

### Effect of enzymes and chemicals on Ytb antigen on intact RBCs

Ficin/Papain Sensitive (variable)

DTT 200 mM/50 mM Sensitive/weakened (thus sensitive to WARM<sup>TM</sup> and

ZZAP)

### In vitro characteristics of alloanti-Ytb

Immunoglobulin class IgG Optimal technique IAT

### Clinical significance of alloanti-Ytb

Transfusion reaction No HDFN No

#### **Comments**

Anti-Yt<sup>b</sup> is rare and usually occurs in sera with other antibodies. The second example of anti-Yt<sup>b</sup> was made by a patient with PNH.

#### Reference

<sup>&</sup>lt;sup>1</sup> Bartels, C.F., et al., 1993. Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism. Am J Hum Genet 52, 928–936.